Kiora Pharmaceuticals (KPRX) director granted 25,000 stock options at $2.63 strike

Rhea-AI Filing Summary

Kiora Pharmaceuticals director David Hollander received a grant of stock options as compensation. He was awarded options covering 25,000 shares of common stock at an exercise price of $2.63 per share, issued under the company’s 2024 Equity Incentive Plan.

The options will become fully exercisable on June 10, 2027 and are scheduled to expire on June 10, 2036 if not exercised. After this grant, Hollander holds 25,000 stock options directly, giving him potential future ownership if the options are exercised.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hollander David

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	25,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 25,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 25,000 options Exercise price: $2.63 per share Underlying shares: 25,000 shares +3 more

6 metrics

Option grant size 25,000 options Stock Option (right to buy) awarded to director

Exercise price $2.63 per share Exercise price for underlying common stock

Underlying shares 25,000 shares Common Stock underlying the option grant

Vesting date June 10, 2027 Date options become fully exercisable

Expiration date June 10, 2036 Option term end if not exercised

Options held after grant 25,000 options Total stock options following this transaction

Key Terms

Stock Option (right to buy), Equity Incentive Plan, Common Stock, exercise price

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Equity Incentive Plan financial

"pursuant to the Issuer's 2024 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

exercise price financial

"conversion_or_exercise_price: 2.6300"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/12/2026 - 04:16 PM Accepted by SEC EDGAR 06/12/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hollander David

(Last) (First) (Middle)

C/O KIORA PHARMACEUTICALS, INC.

169 SAXONY RD., SUITE 212

(Street)

ENCINITAS CALIFORNIA 92024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KIORA PHARMACEUTICALS INC [ KPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.63	06/10/2026		A		25,000		06/10/2027(1)	06/10/2036	Common Stock	25,000	$0	25,000	D

Explanation of Responses:

1. The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027.

Remarks:

	/s/ Melissa Tosca, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Kiora Pharmaceuticals (KPRX) disclose in this Form 4 filing?

Kiora Pharmaceuticals disclosed that director David Hollander received a grant of stock options for 25,000 shares of common stock at a $2.63 exercise price, issued under the 2024 Equity Incentive Plan as a compensation-related award.

How many KPRX shares are covered by David Hollander’s new stock options?

The new stock option grant to David Hollander covers 25,000 shares of Kiora Pharmaceuticals common stock. These options provide the right to buy that number of shares at a fixed $2.63 exercise price if he chooses to exercise them in the future.

What is the exercise price of David Hollander’s Kiora Pharmaceuticals stock options?

The stock options granted to David Hollander have an exercise price of $2.63 per share. This means he can buy Kiora Pharmaceuticals common stock at $2.63 per share once the options are vested and if he decides to exercise them.

When do David Hollander’s KPRX stock options vest and become exercisable?

According to the filing, David Hollander’s stock options will become fully exercisable on June 10, 2027. After that date, he can choose to exercise the options to buy Kiora Pharmaceuticals common shares at the fixed $2.63 exercise price.

When do David Hollander’s Kiora Pharmaceuticals stock options expire?

The stock options granted to David Hollander are scheduled to expire on June 10, 2036. If he does not exercise them by that date, the right to buy Kiora Pharmaceuticals common shares at $2.63 per share will lapse.

Is this KPRX Form 4 transaction an open-market purchase or a compensation grant?

This Form 4 reflects a compensation grant, not an open-market stock purchase. David Hollander received 25,000 stock options from Kiora Pharmaceuticals under the 2024 Equity Incentive Plan, with no cash paid and a $2.63 per-share exercise price set for future exercise.